NCT06539221

Brief Summary

The study aims to investigate the relationship between the small molecule metabolite sphingolipids and asthma clinical features and explore its involvement in asthma pathogenesis.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
3mo left

Started Sep 2024

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
Sep 2024Sep 2026

First Submitted

Initial submission to the registry

August 1, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 6, 2024

Completed
26 days until next milestone

Study Start

First participant enrolled

September 1, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Expected
Last Updated

August 6, 2024

Status Verified

July 1, 2024

Enrollment Period

1 year

First QC Date

August 1, 2024

Last Update Submit

August 1, 2024

Conditions

Asthma

Keywords

asthmaTh17T-cell senescenceSphingolipidsceramide

Outcome Measures

Primary Outcomes (1)

  • lipidomics

    collect blood for lipidomic analysis and in vitro assays

    Day 1

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with asthma who visited or were hospitalized in the Department of Respiratory and Critical Care Medicine of Peking University Third Hospital, who met the asthma diagnostic criteria proposed in the Bronchial Asthma Prevention and Treatment Guidelines and healthy controls without history or symptoms of chronic respiratory disease, allergic status or other conditions that could affect the outcome.

You may qualify if:

  • \. clinical diagnosis of asthma

You may not qualify if:

  • \. Combined with chronic obstructive pulmonary disease, bronchiectasis, pneumonia, obstructive sleep apnea hypopnea syndrome, malignant tumor 2. Combined with acute and chronic respiratory failure 3. Combined with severe cardiovascular disease 4. Pregnant woman.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking university third hospital

Beijing, Beijing Municipality, 100191, China

Location

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Chun Chang

    Peking University Third Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chun Chang

CONTACT

15810075362changc@bjmu.edu.cn

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 1, 2024

First Posted

August 6, 2024

Study Start

September 1, 2024

Primary Completion

September 1, 2025

Study Completion (Estimated)

September 1, 2026

Last Updated

August 6, 2024

Record last verified: 2024-07

Locations

CN(1)